{"id":391651,"date":"2014-05-15T00:00:00","date_gmt":"2014-05-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd1414-biopharma-crohns-disease-moderate-to-severe-decisionbase-us-eu5-2014\/"},"modified":"2026-03-31T09:05:17","modified_gmt":"2026-03-31T09:05:17","slug":"dbaspd1414-biopharma-crohns-disease-moderate-to-severe-decisionbase-us-eu5-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd1414-biopharma-crohns-disease-moderate-to-severe-decisionbase-us-eu5-2014\/","title":{"rendered":"Crohn\u2019s Disease (Moderate to Severe) | DecisionBase | US\/EU5 | 2014"},"content":{"rendered":"<p><em>Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably?<\/em><\/p>\n<p>Treatment for Crohn\u2019s disease (CD)\u2014a relapsing\/remitting inflammatory bowel disease marked by abdominal pain, diarrhea, and complications including gastrointestinal fistulas\u2014requires acute management of disease flares and chronic, long-term maintenance therapy. Moderate to severe CD is typically treated with oral corticosteroids and\/or immunosuppressants to induce and maintain remission, respectively, after which patients graduate to treatment with tumor necrosis factor-alpha (TNF-\u03b1) inhibitors. The first approved TNF-\u03b1 inhibitor for CD, infliximab (Janssen\/Merck\/Mitsubishi Tanabe\u2019s Remicade), remains the market leader for this indication, but the second approved agent in this class, adalimumab (AbbVie\/Eisai\u2019s Humira), is experiencing increasing uptake as a first-line biologic. Emerging therapies with different mechanisms of action and\/or less-burdensome delivery are in clinical development for moderate to severe CD. However, interviewed thought leaders do not expect these drugs to displace the TNF-\u03b1 inhibitors as the dominant drug class for moderate to severe CD, and substantial opportunity exists for additional therapies that can improve on the efficacy and safety of marketed agents.<\/p>\n","protected":false},"template":"","class_list":["post-391651","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391651\/revisions"}],"predecessor-version":[{"id":394774,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391651\/revisions\/394774"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}